<DOC>
	<DOCNO>NCT02569242</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Nivolumab unresectable advanced recurrent esophageal cancer patient fail standard chemotherapy .</brief_summary>
	<brief_title>Study Nivolumab Unresectable Advanced Recurrent Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Men &amp; woman â‰¥20 year age Histologically confirm unresectable advanced recurrent esophageal cancer Refractory intolerant standard therapy ECOG Performance Status score 0 1 A life expectancy least 3 month Current past history severe hypersensitivity antibody product Patients multiple primary cancer Patients metastasis brain meninx symptomatic require treatment Patients active , know suspected autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>